Atyr Pharma Inc (ATYR)

$3.61 -0.14 (-3.73%)
Market Cap 314.78M
Revenue (ttm) 350,000.00
Net Income (ttm) -50.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14,397.14%
Debt to Equity Ratio 0.00
Volume 670,100
Avg Vol 868,104
Day's Range N/A - N/A
Shares Out 83.94M
Stochastic %K 42%
Beta 1.08
Analysts Strong Sell
Price Target $19.40

Latest News on ATYR

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

Dec 12, 2024, 4:00 PM EST - 5 weeks ago

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

Dec 9, 2024, 8:00 AM EST - 5 weeks ago

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

Nov 15, 2024, 8:00 AM EST - 2 months ago

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

aTyr Pharma: The Bull Has Finally Come Out

Oct 24, 2024, 1:00 PM EDT - 3 months ago

aTyr Pharma: The Bull Has Finally Come Out

aTyr Pharma to Present at the LD Micro Main Event XVII in October

Oct 14, 2024, 8:00 AM EDT - 3 months ago

aTyr Pharma to Present at the LD Micro Main Event XVII in October

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Sep 9, 2024, 4:37 AM EDT - 4 months ago

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

aTyr Pharma to Participate in September Investor Conferences

Aug 21, 2024, 8:00 AM EDT - 5 months ago

aTyr Pharma to Participate in September Investor Conferences

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Aug 13, 2024, 4:00 PM EDT - 5 months ago

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

Jun 3, 2024, 8:00 AM EDT - 8 months ago

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 24, 2024, 4:00 PM EDT - 8 months ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

May 15, 2024, 7:00 AM EDT - 8 months ago

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

May 14, 2024, 8:00 AM EDT - 8 months ago

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

May 2, 2024, 4:00 PM EDT - 9 months ago

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma to Participate in April Investor Conferences

Apr 1, 2024, 8:00 AM EDT - 10 months ago

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 11:37 PM EDT - 11 months ago

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Mar 14, 2024, 4:00 PM EDT - 11 months ago

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 11 months ago

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Feb 21, 2024, 8:00 AM EST - 11 months ago

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

Jan 18, 2024, 8:00 AM EST - 1 year ago

aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Nov 13, 2023, 8:00 AM EST - 1 year ago

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

aTyr Pharma to Present at November Investor Conferences

Nov 1, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present at November Investor Conferences

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

Sep 11, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

Aug 9, 2023, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

Jun 20, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

May 25, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

May 11, 2023, 4:00 PM EDT - 1 year ago

aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

May 9, 2023, 4:00 PM EDT - 1 year ago

aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

Mar 20, 2023, 8:00 AM EDT - 1 year ago

aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

Mar 10, 2023, 5:12 PM EST - 2 years ago

aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

Mar 9, 2023, 4:00 PM EST - 2 years ago

aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update

aTyr Pharma to Present at March Investor Conferences

Mar 8, 2023, 8:00 AM EST - 2 years ago

aTyr Pharma to Present at March Investor Conferences

aTyr Pharma Announces Commencement of Public Offering of Common Stock

Feb 8, 2023, 4:11 PM EST - 2 years ago

aTyr Pharma Announces Commencement of Public Offering of Common Stock

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

Jan 19, 2023, 8:00 AM EST - 2 years ago

aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

Jan 18, 2023, 8:00 AM EST - 2 years ago

European Commission Grants Orphan Drug Designation for aTyr Pharma's Efzofitimod for Treatment of Sarcoidosis

aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 8:32 PM EST - 2 years ago

aTyr Pharma, Inc. (LIFE) Q3 2022 Earnings Call Transcript

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

Nov 10, 2022, 4:00 PM EST - 2 years ago

aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update

aTyr Pharma to Present at Upcoming Investor Conferences

Nov 10, 2022, 8:00 AM EST - 2 years ago

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

Nov 3, 2022, 8:02 AM EDT - 2 years ago

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

aTyr Pharma to Present at the Jefferies London Healthcare Conference

Oct 25, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the Jefferies London Healthcare Conference

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

Oct 11, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

Sep 29, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies

aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

Sep 6, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2022 Results - Earnings Call Transcript

Aug 15, 2022, 11:13 PM EDT - 2 years ago

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2022 Results - Earnings Call Transcript

aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 15, 2022, 4:00 PM EDT - 2 years ago

aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

Aug 11, 2022, 8:03 AM EDT - 2 years ago

aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

Aug 4, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

Jun 14, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment

aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

Jun 13, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference

aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference

Jun 1, 2022, 8:00 AM EDT - 2 years ago

aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference